Show simple item record

dc.contributor.authorBertoglio, Federico
dc.contributor.authorMeier, Doris
dc.contributor.authorLangreder, Nora
dc.contributor.authorSteinke, Stephan
dc.contributor.authorRand, Ulfert
dc.contributor.authorSimonelli, Luca
dc.contributor.authorHeine, Philip Alexander
dc.contributor.authorBallmann, Rico
dc.contributor.authorSchneider, Kai-Thomas
dc.contributor.authorRoth, Kristian Daniel Ralph
dc.contributor.authorRuschig, Maximilian
dc.contributor.authorRiese, Peggy
dc.contributor.authorEschke, Kathrin
dc.contributor.authorKim, Yeonsu
dc.contributor.authorSchäckermann, Dorina
dc.contributor.authorPedotti, Mattia
dc.contributor.authorKuhn, Philipp
dc.contributor.authorZock-Emmenthal, Susanne
dc.contributor.authorWöhrle, Johannes
dc.contributor.authorKilb, Normann
dc.contributor.authorHerz, Tobias
dc.contributor.authorBecker, Marlies
dc.contributor.authorGrasshoff, Martina
dc.contributor.authorWenzel, Esther Veronika
dc.contributor.authorRusso, Giulio
dc.contributor.authorKröger, Andrea
dc.contributor.authorBrunotte, Linda
dc.contributor.authorLudwig, Stephan
dc.contributor.authorFühner, Viola
dc.contributor.authorKrämer, Stefan Daniel
dc.contributor.authorDübel, Stefan
dc.contributor.authorVarani, Luca
dc.contributor.authorRoth, Günter
dc.contributor.authorČičin-Šain, Luka
dc.contributor.authorSchubert, Maren
dc.contributor.authorHust, Michael
dc.date.accessioned2021-03-24T13:37:17Z
dc.date.available2021-03-24T13:37:17Z
dc.date.issued2021-03-11
dc.identifier.citationNat Commun. 2021 Mar 11;12(1):1577. doi: 10.1038/s41467-021-21609-2.en_US
dc.identifier.pmid33707427
dc.identifier.doi10.1038/s41467-021-21609-2
dc.identifier.urihttp://hdl.handle.net/10033/622794
dc.description.abstractCOVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, a new recently emerged sarbecovirus. This virus uses the human ACE2 enzyme as receptor for cell entry, recognizing it with the receptor binding domain (RBD) of the S1 subunit of the viral spike protein. We present the use of phage display to select anti-SARS-CoV-2 spike antibodies from the human naïve antibody gene libraries HAL9/10 and subsequent identification of 309 unique fully human antibodies against S1. 17 antibodies are binding to the RBD, showing inhibition of spike binding to cells expressing ACE2 as scFv-Fc and neutralize active SARS-CoV-2 virus infection of VeroE6 cells. The antibody STE73-2E9 is showing neutralization of active SARS-CoV-2 as IgG and is binding to the ACE2-RBD interface. Thus, universal libraries from healthy human donors offer the advantage that antibodies can be generated quickly and independent from the availability of material from recovering patients in a pandemic situation.en_US
dc.language.isoenen_US
dc.publisherNPGen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleSARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.en_US
dc.typeArticleen_US
dc.identifier.eissn2041-1723
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalNature communicationsen_US
dc.source.volume12
dc.source.issue1
dc.source.beginpage1577
dc.source.endpage
refterms.dateFOA2021-03-24T13:37:20Z
dc.source.journaltitleNature communications
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Bertoglio et al.pdf
Size:
4.964Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International